@Singapore88. Telur pun sudah semakin kempis, kecut.
Mana 8dragon. Tak nak main tendang bola telur sama ke? He He

@zzzzzzz, Saya ada telur. Bukan senang nak kick orang. Walaupun orang yang sebenarnya nampak macam lawan.

@zzzzzzz. Tak apa lah kalau bukan. Mungkin saya silap.

zzzzzzz Lu belum keluar group tele kah
--------------
Saya mungkin akan keluar jika disingkirkan, atau bila saya sudah tiada kepentingan saham lagi dalam kaunter ini.

ding ding pun belum keluarkan? Pun muka tebal juga kan?

@18KHarmoni. terpulang kamulah. Bolehlah duplicate lagi ID baru. Supaya nampak ramai orang mahu tengok saham jatuh.
Setiap orang punya matlamat sendiri. Teruskan usaha awak.

@OKU_2020. Saya belum lari. Belum melingkop. Atas kertas, memang lebih kurang 60% rugi.
Siapa tahu, politik Malaysia dah jadi BUBUR.....

@zzzzzzz. Saya masih ada. masih bertahan.

@18KHarmoni. Ya. Kita cuba cari dan kongsi maklumat. Bukan sekadar nak burukkan saja company tanpa maklumat, seperti yang dibuat oleh naysayer/hater.

Peace99 ---on the 2 passages from P. 39 of the RI circular:
1. "Assuming all 112,015,160 outstanding ESOS Options are exercised at the exercise
price of RM0.05409 per ESOS Option..."
I suppose this means about 20mil ESOS options have yet to be exercised, correct?
----------------
The circular dated 11 June 2021. In my opinion, at that date, the outstanding ESOS option was 112,015,160 units. On 5 July 2021, 46,209,193 units of the ESOS listed.
Therefore, I think 65,805,967 units of outsatanding ESOS options left...

ESOS sekali lalun dapat free share
---------------
Dapat free share. Dari mana awak belajar saham ni. Betulkan fakta, khususnya fakta yang
akan dibaca oleh newbie. Jangan pula tuduh company atau pihak yang promote share "penipu",
sedangkan fakta anda sendiri "menipu". He He

@OKU_2020. Tadi sokong kata PN17 company. Tak kan nak beli kot.
Bahaya. Nanti kena preqqq lagi. He He

8dragon NG buat announcement demi announcement, projek demi projek. Cuba tanya dari dulu sehingga sekarang berapa projek yang telah berjaya dilaksanakan ...
-----------------
Khusus untuk naysayer tanpa "telur" sahaja.
Baca ini.

1. https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

atau ini, (sama saje)

2. https://www.malaysiastock.biz/Blog/BlogArticle.aspx?tid=24605

@OKU_2020. Awak ni memang Orang Kurang Upaya lah.

Ini cerita progress kepada proposal syarikatlah.
Betul atau tidak betul ceritanya, bacalah dahulu berita. kemudian buat judgement.

Mentang-mentang nak badmouth, sembur saja cerita naysayer tanpa ambik tahu apa cerita.

Singapore88 Myr62 millions,,big amount
-----------------
Yes. The proposed Lifecare Specialist Project has a proposed gross development value estimated at RM1.6 billion.

An update on MOU no. 7:

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3173190

b) Based on an announcement at BURSA dated 6 July 2021.

- Board of Directors of NEXGRAM is pleased to announce that NEXGRAM BIOMEDIC SDN BHD (“NBSB” OR “PURCHASER”) had on 1 July 2021 entered into a Sale and Purchase Agreement (“SPA”) with PERBADANAN KEMAJUAN NEGERI MELAKA (“PKNM” OR “VENDOR”) to acquire a piece of 99 years of leasehold land held under PT 8839, Mukim Bukit Baru, District of Melaka Tengah, State of Melaka with measuring an area of approximately 10.031 hectares (equivalent to 24.78 acres) (“the said Land”) with a purchase consideration of Ringgit Malaysia Sixty One Million Five Hundred Twenty Six Thousand Seven Hundred Fifty Seven and Sen Sixty (RM61,526,757.60) only (“the Purchase Price”) calculated at the rate of Ringgit Malaysia Fifty Seven (RM57.00) only per square foot (“Proposed Land Acquisition”).

- The Proposed Land Acquisition shall be satisfied in cash by internal generated funds, financing and/or any future corporate exercise which will be announced in due course.

Remark:
1. The said SPA to acquire the land is subject to, the company:
(i) appoint an Adviser,
(ii) issue a circular which includes the information set out in Appendix 10B to its shareholders; and (iii) seek shareholders’ approval of the transaction in a general meeting.

8dragon Get ready for right issues on the way....,Ozura will get it for 1.5 cent, so still making tons of money, but all bilis and small investors will suffer ...
---------------
Wow. 8dragon sudah mahu jual telur pula ya.
Telur Ayam???
Atau telur... ?
Opss. Lupa pula. Telur sendiri memang tak ada. He He

@8dragon. Asal telur tak hilang sudah... He He He

@ zzzzzzz and 8dragon. You are allowed to make your own decisions.

For me. Agi idup agi ngelaban. He He. TAYOR

@Peace99. ........and will borrow from bank if RI not able to raise the money needed. (But i think it will be able to).
----------------------
I positively think that the RI will be a success for Kanger.

@hlh1962.

1. For the RI:
The EGM already approved the RI, and the BURSA also had approved the listing and quotation of the RI shares.

We have to wait for an announcement by Kanger in relation to the entitlement date of the RI.

2. For the breakdown of their last 5QR 2021, I just referred to:

https://www.bursamalaysia.com/market_information/announcements/company...

Note: Please download the pdf file attached.

@hlh1962. My idea is, if they don't push-up the price at least a bit higher than the RI price, the company's RI would be a FAILURE.
I, myself won't subscribe the RI, if the price before the ex-date just lingering @ 5.5 - 6 sen.

I hope Kanger's RI case will not be an exceptional case...
He He. Apa-apa pun yang akan terjadi.... TAYOR.

(b) relocation of our bamboo processing and manufacturing operations from Ganzhou,
PRC to Jingzhou, PRC is still ongoing hence lesser revenue was contributed from the
subsidiary in Ganzhou.

@8dragon. Please read carefully all the information given to you......

@8dragon. Yes, I know that there are some investors still keep an eye on this counter,
including a few naysayers / haters in this group. He He

MY PERSONAL NOTES BASED ON THE 3QR 2021 REPORT:

1. The approved capital reduction exercise was not yet been taken into account in the 3QR 2021. Probably will be done in 4QR 2021 accounts.

2. No specific report on the progress of the revenue from Indonesian, RAFA Agreement on the medical gloves and gown.


NOTABLE NOTES FROM THE 3QR 2021 REPORT:

1. Healthcare continues to progress well, with government project SafeTravelPass COVID-19 entry-registration, payment and management of Quarantine-Station and government services contributing positively in current financial year.

My personal comment:
It’s a POSITIVE NOTE, as the company recognized there is a contribution from TracAPM – SafeTravelPass in the current financial year. The system are in a business and generating revenue to Nexgram, instead of Malaysia is currently closing her borders.


2. COVID-19 tests partnership with government is looking at positive return in coming quarter after much capital investment in last two (2) quarters, in view of taking part of mass screening assignment engaged with government health facilities.

My personal comment:
It’s a POSITIVE NOTE, as the company recognized that in the last two quarters, the cost from a big capital investment has pressured the profitability of the company quarters, but the company expected more positively on its profitability in incoming quarters, thanks to Nexgram’s involvement in the mass screening of Covid-19 assignment engaged with the government health facilities.


3. Government project capital investment continue to weight on current quarter which is normal for concession early investment.

My personal comment:
It’s a NEGATIVE NOTE for short term, as the company recognized that the big capital investment done on the secured government project gave more cost to the company and affected the profitability in the last quarter.


4. The Group other healthcare segment is expanding on capacity resulted in further cost. The healthcare segment had experienced lower margin and recent success in contracts shall expect to contribute to bottom line in coming quarter.

My personal comment:
It’s a NEGATIVE NOTE, as the company recognized further cost will be occurred cause by further expanding in its healthcare business. In addition, will the added cost and the current lower margin of healthcare business will give more pressure on the company’s profitability in near future?

On the POSITIVE SIDE, the company has successfully secured the contracts in healthcare business and its expected to contribute positively in 4QR 2021.

For updates, please refer to the blog article:

SOME ANALYSIS ON THE 3QR 2021 RESULT OF NEXGRAM (0096)

https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

SOME ANALYSIS ON THE 3QR 2021 RESULT OF NEXGRAM (0096)

https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

NOTABLE NOTES FROM THE 3QR 2021 REPORT:

1. Healthcare continues to progress well, with government project SafeTravelPass COVID-19 entry-registration, payment and management of Quarantine-Station and government services contributing positively in current financial year.

My personal comment:
It’s a POSITIVE NOTE, as the company recognized there is a contribution from TracAPM – SafeTravelPass in the current financial year. The system are in a business and generating revenue to Nexgram, instead of the Malaysia is currently closing her borders.

2. COVID-19 tests partnership with government is looking at positive return in coming quarter after much capital investment in last two (2) quarters, in view of taking part of mass screening assignment engaged with government health facilities.

My personal comment:
It’s a POSITIVE NOTE, as the company recognized that in the last two quarters, the cost from a big capital investment has pressured the profitability of the company quarters, but the company expected more positively on the profitability in incoming quarters, thanks to Nexgram’s involvement in the mass screening of Covid-19 assignment engaged with the government health facilities.


3. Government project capital investment continue to weight on current quarter which is normal for concession early investment.

My personal comment:
It’s a NEGATIVE NOTE for short term, as the company recognized that the big capital investment done on the secured government project gave more cost to the company and affected the profitability in the last quarter.

4. The Group other healthcare segment is expanding on capacity resulted in further cost. The healthcare segment had experienced lower margin and recent success in contracts shall expect to contribute to bottom line in coming quarter.

My personal comment:
It’s a NEGATIVE NOTE, as the company recognized further cost will be occurred cause by further expanding in its healthcare business. In addition, will the added cost and the current lower margin of healthcare business will give more pressure on the company’s profitability in near future?

On the POSITIVE SIDE, the company has successfully secured the contracts in healthcare business and its expected to contribute positively in 4QR 2021.

8dragon I thought MZM2511 estimated over RM100 in revenue...
--------------------
RM100 million revenue for financial year 2021. Please read carefully.

The total revenue for three quarters already RM73.957 million. If the revenue for 4QR can record at least RM27 million, therefore my forecast will be meet, The FY 2021 revenue will be at least RM100 million.

The revenue up tremendously, but can't show profit.

Individual Quarter
Revenue dropped by RM10.2 million or 90% in the current financial quarter ended
31 March 2021 (“Q5 2021”) as compared to the corresponding quarter ended 31 March 2020
(“Q1 2020”) mainly due to:-

(a) minimal business operations were allowed in many countries as a result of overnment mandated lock downs due to the novel coronavirus or COVID-19 outbreak which has
turned into a global pandemic hence less revenue was generated, although some of the
countries have slowly resumed business activities coupled with the festive season
being The Chinese New Year where many business in the PRC were closed for the
celebration of the festival; and

(b) relocation of our bamboo processing and manufacturing operations from Ganzhou,
PRC to Jingzhou, PRC is still ongoing hence lesser revenue was contributed from the
subsidiary in Ganzhou.

The gross loss recorded in Q5 2021 as compared to gross profit recorded in Q1 2020 mainly
due to effort by the management to clear some of the old stocks hence higher discount was
given.

Overall, the Group recorded loss before taxation of RM16.4 million in Q5 2021 as compared
to loss before taxation of RM4.4 million in Q1 2020 mainly due to insufficient revenue
generated to defray the expenses, in particular the sale of strand woven bamboo flooring was
largely affected by the relocation of our bamboo processing and manufacturing operations
from Ganzhou, PRC to Jingzhou,

PRC. Furthermore, the Group also incurred some nonrecurring expenses such as bad debts written off of RM2.0 million, impairment loss on trade and other receivables of RM50.0 million, intangible assets written off of RM1.5 million, inventories written off of RM0.3 million and the share based payment of RM3.9 million in Q5 2021 although the impact of these expenses were mitigated by the recognition of the fair value gain on investment properties of RM46.0 million.

The incoming 5QR 2021 should be released on the end of July 2021. The 5QR 2021 will reports the results of businesses activities from 1 January 2021 up to 31 March 2021.

Please be noted that Kanger has approved the change of financial year end from 31 Dec 2020 to 31 Mar 2021. Therefore, the first set of accounts after the change shall be for a period of 15 months from 1 Jan 2020 to 31 Mar 2021. That means, the last quarterly report for financial year end of 31 March 2021 should be referred to the 5QR 2021.

JUST TO GIVE SOME EXPECTATION FROM MY LITTLE OBSERVATION ON THEIR LAST QUARTERLY REPORT WHICH IS 4QR 2021 which was reported on 31 March 2021.

1. I noticed that all the revenue of the company for the last QR was derived only from the bamboo flooring and related goods businesses. There are no another substantial source of revenue.

2. Their sales mainly derived from the Republic of China market, without any sales from the regular markets outside China, such as Malaysia, New Zealand, Mexico, United Arab Emirates and other countries. This happened caused by the Covid-19 pandemic.

3. The company’s sales was decreased mainly due to:

(a) minimal business operations were allowed in many countries as a result of government mandated lock downs due to the novel coronavirus or COVID-19 outbreak which has turned into a global pandemic hence less revenue was generated, although some of the countries have slowly resumed business activities; and

(b) relocation of our bamboo processing and manufacturing operations from Ganzhou, PRC to Jingzhou, PRC is still ongoing hence lesser revenue was contributed from the subsidiary in Ganzhou.

4. Prospects for the 5QR 2021 (financial period ending 31 March 2021) as reported by the company:

PRC’s strong economic growth has led to increasingly affluent consumers who now have the
purchasing power as well as the willingness to pay to enhance individual lifestyles for greater
comfort and pleasure. The modernisation and urbanisation of the country has also caused a
growth in PRC’s property construction industry, an industry that the bamboo flooring market is
dependent on for the consumption of its products. Under its 13th Fiver-Year Plan (2016 - 2020),
PRC aims to double its 2010 GDP and the 2010 per capita income of both urban and rural
residents by 2020 and will focus more on green and low-carbon industries. This is envisaged
to positively affect the bamboo flooring market. In addition, bamboo flooring products are
increasingly welcomed by the consumer due to merits like environmental friendliness and high
price-to-performance ratio.


5. My forecast for the company’s 5QR 2021 is, as the company sales for this quarter mainly focused on the Republic of China market, the revenues would be hardly to increase, therefore it will affect the company’s profitability. It’s good for the company if the company can show a little improvement in its revenue and reduces their net loss for this quarter report

JUST A THEORY TO SHARE

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.

AFTER ALL. TAYOR.

The company announced that the Board had on 26 April 2021 ("Price-Fixing Date") resolved to fix the issue price of the Rights Shares at RM0.06 per Rights Share ("Issue Price").

@DRwarrant. Saya tak nak layan dah ini zzzzzzz. Layan buat pening kepala saja.
Saya nak biar saja dia cakap apa. Biar saja dia nak cakap apa.
Saya nak bagi saja idea atau info yang ada. Ini forum awam kan?
Kalau layan dia, kita pun jadi mengarut sama...

@kenshiro. As I'm the current shareholder of this stock, I won't cut loss just to please the hater/naysayers advice.

Beside, I suspect something wrong with your new identity in this forum. Newly registered identity and straight forwardly whacking this counter. IT IS SOMETHING FISHY HERE....

@kenshiro. Another Nexgram hater (maybe also MZM2511 hater). Once registering the new id, whacking Nexgram.

Your idea is yours. But my ideas is mine. Let us see what happen in the future.
The ICPS problem already counted in for the long time share holder of Nexgram.
For the newbie in this counter, please be alert about that issue

ding ding...... zzzzzzz

ini nama pun boleh tukar. Apa masalah dengan tukar nama group?

@Lightspeed. Nama pun lightspeed. Buka akaun baru ni,mungkin khusus post untuk kaunter Nexgram. Entah siapa punya double atau triple id pun tak tahu ni.

Apa-apa pun kita tunggu saja QR.......

The new link to the new blog article on Kanger. I re-posted it with the new title: Kanger (0170) Has A Great Prospect To Secure Its Sinopharm Covid-19 Vaccine Distributorship In Malaysia.

https://klse.i3investor.com/blogs/mzm511/2021-06-27-story-h1567059168-Kanger_0170_Has_A_Great_Prospect_To_Secure_Its_Sinopharm_Covid_19_Vacci.jsp

@zzzzzzz. Mainlah wayang cara awak. Itu mungkin terbaik untuk awak.
Saya budak-budak akan terus main wayang budak-budak saja. He He

Nexgram untuk orang yang ada telor dan guts saja @zzzzzzz.

Kalau lembik dan tak berani mengambil risiko, tempatnya bukan
dalam kaunter ini.
Nak selamat, masuk melabur dalam saham Tenaga sajalah.
Atau simpan duit dalam bank.

@MuttsInvestor

I believe that the Sinopharm vaccine is now under the registration process with NPRA, and its supposed to be approved by NPRA by August 2020, its based on the Khairy's latest statement.

My only hope is, the registration process of Sinopharm was done by Kanger, and not by any other parties, because as per my understanding, earlier Kanger has signed a distributorship agreement with Sinopharm Group Hunan Changde.

@8dragon and @zzzzzzz. Only the company QR will give true answers.

@BilisMasin. Adakah kita semua yang telah beli saham Kanger atau akan beli saham kanger sebenarnya seprti dikatakan kawan kita ini?

-------------------

aiman77 Orang gila jer beli counter nie

TracAPM
End-to-End Express Digital Facilitations in Malaysia Airports & Borders

Trac and Trace
– Traveller Registration
– E-Certs & Vaccine Passports Check
– QR Code Scan-n-Go
– Queue Numbering System*
– Biometric Registry*

---------------

Awak lihat sana. Vaccine Passport Check. Bukannya untuk keluarkan vaccine passport.

Berdasarkan kefahaman saya, kalau nanti TracAPM diterima guna untuk semua agensi yang dinyatakan, penggunaan MYSEJAHTERA sebagai official vaksin cert bagi pihak kerajaan Malaysia tidak memberi kesan, kerana fungsi TracAPM - TracVirus SafeTravelPass bukan sekadar untuk menyedia vaksin passport. Ia juga boleh dikoordinasi /link dengan MYSEJAHTERA untuk membaca vaksin cert dan menjalankan fungsi lainnya sebagai sistem yang digunakan untuk kawalan pergerakan pelancong keluar atau ke dalam , khususnya pelancong ke dalam negara.

Bisnis utama yang boleh diperoleh dari tracapm safetravelpass nanti ialah komisen dari pendaftran pelancong untuk hotel dan kuarantin serta dapat membekalkan perkhidmatan covid-19 test.

@aiman77. Mudah saja aiman77. Kawan-kawan boleh tengok sini. Adakah sebelum ini
syarikat tidak pernah membuat untung????

https://klse.i3investor.com/servlets/stk/fin/0170.jsp

Pelabur atau bakal pelabur yang bijak akan cari lebih maklumat. Kenapa dan mengapa?

Pencapaian syarikat bukannya statik.
Dalam keadaan sebelum ini sehingga sekarang berlaku pandemik Covid-19,
syarikat yang sebelum ini kukuhpun akan terjejas, terutama jika perniagaannya
banyak dipengaruhi oleh kesan pandemik.

Lihat juga prospek syarikat untuk diversify bagi mengatasi masalah semasa syarikat.

@18Kharmoni.

aiman77 Orang gila jer beli counter nie
-------------------
Memang aiman77 telah mengesahkan semuanya... Anda boleh duduk diam saja..
BUKAN DUDUK DIAMLAH, TAPI BAGI TAHNIAH LAGI KAT DIA. He He.
Mana telor dan maruah awak?

@MuttsInvestor.

I think the answer is here:

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

AND LATER FOLLOWED BY:

I know SINOPHARM and all that are going to be registered here,” Khairy added.